STSA 1002
Alternative Names: STSA-1002Latest Information Update: 28 Aug 2025
At a glance
- Originator Staidson Beijing BioPharmaceuticals
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Adult respiratory distress syndrome
- Phase I Vasculitis
- No development reported SARS-CoV-2 acute respiratory disease
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in SARS-COV-2 acute respiratory disease(In volunteers) in China (IV, Infusion)
- 28 Aug 2025 No recent reports of development identified for phase-I development in SARS-COV-2 acute respiratory disease(In volunteers) in USA (IV, Infusion)
- 27 Apr 2025 Staidson (Beijing) Biopharmaceuticals completes a phase I/II trial in Adult Respiratory Distress Syndrome in China (Injection) (NCT06038916)